Efficacy and safety of recombinant von Willebrand factor in on-demand treatment of children with von Willebrand disease: up to 4 years of phase 3/3b follow-up


Bergmann S., Ahuja S., Albayrak C., Cnossen M. H., Dunn A. L., Labarque V., ...More

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, vol.10, no.5, 2026 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 10 Issue: 5
  • Publication Date: 2026
  • Doi Number: 10.1016/j.rpth.2026.106817
  • Journal Name: RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals, Health Research Premium Collection (ProQuest)
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Background Recombinant von Willebrand factor (rVWF) is approved to treat von Willebrand disease (VWD) in adults and was recently approved in the United States for pediatric on-demand and perioperative treatment. Objectives To evaluate the efficacy and safety of rVWF, without or with recombinant factor VIII (rFVIII), for on-demand treatment of bleeding events (BEs) in pediatric patients with VWD. Methods A prospective, open-label, phase 3 study (NCT02932618) evaluated efficacy and safety of on-demand rVWF, without or with rFVIII, for treating nonsurgical BEs (for up to 18 months) in patients aged <18 years with severe VWD (VWF:ristocetin cofactor <20 IU/dL). The primary end point was treatment success (mean efficacy, <2.5; 4-point scale, 1 [excellent] to 4 [none]). Patients completing the study could enter a phase 3b continuation study (NCT03879135), evaluating safety and efficacy of rVWF for 3 additional years. Results Of 25 patients in the phase 3 study, 11 (44%) had type 3 VWD. Eighteen patients reported 104 BEs treated with on-demand rVWF; all were treated successfully (mean [SD] efficacy, 1.01 [0.04]). All 98 BEs with efficacy ratings were rated excellent or good. Most BEs (82%) were treated with 1 rVWF infusion; 27% were treated with additional rFVIII. rVWF was well tolerated, with no adverse events leading to study or treatment discontinuation. No thromboembolic events, severe hypersensitivity reactions, or treatment-related serious adverse events occurred. No neutralizing or binding antibodies to rVWF were observed. Efficacy and tolerability of on-demand rVWF were maintained in the continuation study. Conclusion rVWF, without or with rFVIII, was efficacious for treating nonsurgical BEs in pediatric patients with severe VWD, with efficacy maintained for up to 4 years and no new safety findings.